BEIJING & SHANGHAI & HONG KONG--(BUSINESS WIRE)--Dec 10, 2025--
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen,” SSE: 688796; HKEX: 02315), a global biotechnology company advancing innovative drug discovery, today announced its successful listing on the Shanghai Stock Exchange STAR Market. This follows the Company’s listing on the Hong Kong Stock Exchange in September 2022 and marks a significant milestone in establishing Biocytogen as the first “H+A” dual-listed global drug innovator, reinforcing its mission to become the global headstream of new drugs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209006205/en/
The Company’s IPO price was set at 26.68 RMB per share, with an opening price of 58 RMB, representing a 117% increase over the offering price. Based on the opening price, Biocytogen’s market capitalization exceeds 25.9 billion RMB.
Biocytogen’s proprietary RenMice ® platforms (RenMab™, RenLite ®, RenNano ®, RenTCR mimic™) enable the discovery of fully human monoclonal, bispecific, multispecific, ADC, VHH, and TCR mimic antibodies across more than 1,000 druggable targets. Leveraging a library of over one million authentic antibody sequences, these platforms provide partners with grab-and-go access to high-quality therapeutic molecules—significantly accelerating antibody drug discovery timelines. To date, the Company has advanced more than 40 PCC-to-IND stage assets and established over 280 global discovery partnerships, including more than 10 clinical or near-clinical programs successfully out-licensed. Complementing this, Biocytogen offers a globally leading portfolio of more than 4,390 off-the-shelf target-humanized mouse models, supporting the preclinical evaluation of bispecific antibodies, antibody–drug conjugates (ADCs), nucleic acid–based therapeutics, and other innovative modalities.
The successful STAR Market listing positions Biocytogen for further global expansion, platform commercialization, and strategic capital deployment. Leveraging the synergies of its “H+A” dual-listing structure, the Company will continue deepening collaborations with international partners, strengthening its technology platforms, and driving the discovery of novel therapies to benefit global healthcare.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice ® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice ® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
Biocytogen Successfully Lists on the STAR Market
LONDON--(BUSINESS WIRE)--Dec 10, 2025--
Hims & Hers is deepening its commitment to the UK by bringing access to its comprehensive Weight Loss Programme to customers. This expansion includes the official introduction of the Hers platform, helping eligible women across the UK receive access to this holistic weight management care.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210113886/en/
Sixty four percent of UK adults are overweight or living with obesity, yet access to GLP-1 treatment plans remains challenging on the NHS, and via the private sector due to surging demand and escalating costs. Removing barriers to care, the Hims & Hers digital platform provides eligible British women and men seamless access to its comprehensive, doctor-designed Weight Loss Programme.
Following a thorough, and clinically robust intake assessment conducted by GMC-registered doctors, eligible customers now have access to transparent pricing and personalised weight management programmes, which may include branded GLP-1 options, such as Mounjaro or Wegovy, and the oral non-prescription treatment option, Orlos. Licensed clinicians assess each individual’s medical history, suitability, and contraindications to guide appropriate treatment decisions. Critically, all customers have access to comprehensive support, including 24/7 care team access and content to help improve nutrition, movement, and sleep-based habits along their weight loss journey. This holistic programme is designed to support long-term health, helping customers manage their weight and adopt sustainable lifestyle habits.
Now for the first time through Hers, women in the UK deemed clinically suitable can access a new standard of weight management care that blends convenience with personalised support at every step of their journey. Hers’ customers receive ongoing clinician support through follow-ups and asynchronous messaging, along with treatment adjustments when necessary, keeping care seamless, conversational, and customer-centered. Hers is more than just a telehealth platform; it's where clinical experience meets thoughtful care, resetting women’s expectations and standards for comprehensive and convenient care.
"The launch of Hims & Hers’ comprehensive Weight Loss Programme and the vital introduction of the Hers platform, our dedicated platform for women, represents a significant deepening of our commitment to the UK,” said David Meinertz, GM International of Hims & Hers. “Our doctor-designed treatment plans will complement the NHS by providing accessible, evidence-based, and sustainable long-term weight management care to those who need it, discreetly and conveniently. Our proven model is grounded in clinical excellence, oversight, and convenience, ensuring that every customer receives the thoughtful, thorough, and high-quality care they deserve."
"Obesity is a global epidemic, and the scale of the challenge in the UK requires a comprehensive solution that prioritises long-term health over quick fixes," said Craig Primack MD, Head of Weight Loss at Hims & Hers. "Bringing our trusted, comprehensive approach to the UK will help people lead fuller and healthier lives. And with the launch of the Hers platform, we are ensuring women have access to the dedicated, personalised care they need. Pairing clinically-proven treatments like GLP-1s with holistic support across nutrition and exercise helps make sustainable weight management achievable for the millions battling obesity today."
Launching its Weight Loss Programme marks the company’s continued progress in its mission to make personalised care accessible to millions of people across the UK. Hims & Hers plans to continue to expand into more offerings as demand for access to personalised care continues to grow.
About Hims & Hers Health, Inc
Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalises health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy achievable. No two people are the same, so the company provides access to personalised care designed for progress. For more information, please visit www.forhims.co.uk and www.forhers.co.uk
Cautionary Note Regarding Forward-Looking Statements
This communication includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes,” “estimates,” “anticipates,” “expects,” “intends,” “plans,” “assume,” “may,” “will,” “likely,” “potential,” “projects,” “predicts,” “continue,” “goal,” “strategy,” “future,” “forecast,” “target,” “outlook,” “opportunity,” “project,” “confidence,” “foundation,” “groundwork,” or “should,” or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, statements regarding our launch and expansion of the program, the introduction of the Hers platform in the UK, our expectations regarding customer adoption and subscriber growth, the pricing and availability of GLP-1 or other treatment options, our market opportunity in the UK, the growth of our weight management offering internationally, and our ability to comply with applicable legal, regulatory, and clinical requirements in the UK and other markets. These statements are based on management’s current expectations, but actual results may differ materially due to various factors.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, the forward-looking statements contained in this communication are based on our current expectations, assumptions, and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the performance and acceptance of our weight loss specialty in the UK; our ability to successfully launch and scale the Hers platform in the UK; uncertainties relating to the availability, pricing, or supply of GLP-1 medications; changes in medical guidelines or regulatory requirements in the UK; competitive developments; operational and marketing costs; the impact of macroeconomic conditions on consumer demand; and other factors described in the Risk Factors and other sections of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and other reports we file from time to time with the Securities and Exchange Commission.
Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The forward-looking statements contained in this communication are made only as of December 10, 2025. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from those made in or suggested by the forward-looking statements in this communication.
Now for the first time through Hers, women in the UK deemed clinically suitable can access a new standard of weight management care that blends convenience with personalised support at every step of their journey.
